As part of the deal, some of Pfizer’s drugs will be offered in the United States through a direct-to-consumer website, ...

Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand ...

Enfortumab vedotin plus pembrolizumab improved EFS, OS, and pCR rates in MIBC patients ineligible for cisplatin-based chemotherapy. The combination therapy showed a median EFS and OS that were not ...

Yahoo Finance is chronicling the latest news and updates on President Trump's plans to impose tariffs on goods from other ...

Biotech stocks rebound after years of weakness as M&A, lower rates and easing policy fears draw investors back to the sector.

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

The impact of digital transformation, increased regulation, rising costs, bouncing tariffs and volatile geopolitics are just some of the big issues keeping Australian business leaders up at night.

U.S. President Donald Trump and Germany’s Merck KGaA announced a deal to sharply cut the price of key IVF drugs in the United ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...